In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 59514-89-5, name is 2,4-Dichloro-1,8-naphthyridine, introducing its new discovery. SDS of cas: 59514-89-5
MERCK PATENT GMBH; DORSCH, Dieter; JONCZYK, Alfred; HOELZEMANN, Guenter; AMENDT, Christiane; ZENKE, Frank
The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases playsa role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 59514-89-5, and how the biochemistry of the body works.SDS of cas: 59514-89-5
Reference£º
1,557-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N551 – PubChem